TipRanks
Advertisement
Advertisement
Rezolute: FDA’s Constructive Stance on Ersodetug and Strategic Dual-Indication Path Support Unchanged $10 Price Target and Buy Rating
PremiumRatingsRezolute: FDA’s Constructive Stance on Ersodetug and Strategic Dual-Indication Path Support Unchanged $10 Price Target and Buy Rating
21h ago
Rezolute Advances Pre-BLA Strategy for Ersodetug Program
Premium
Company Announcements
Rezolute Advances Pre-BLA Strategy for Ersodetug Program
1d ago
Rezolute announces FDA recommendation to hold pre-BLA meeting for ersodetug
Premium
The Fly
Rezolute announces FDA recommendation to hold pre-BLA meeting for ersodetug
1d ago
Douglas Tsao Boosts RZLT Price Target to $10 and Reiterates Buy on Strong upLIFT Clinical Momentum
PremiumRatingsDouglas Tsao Boosts RZLT Price Target to $10 and Reiterates Buy on Strong upLIFT Clinical Momentum
11d ago
Rezolute price target raised to $10 from $5 at H.C. Wainwright
Premium
The Fly
Rezolute price target raised to $10 from $5 at H.C. Wainwright
11d ago
Rezolute: Buy Rating Reiterated as FDA Engagement and Strong HI Data Support Unchanged $6 Price Target
Premium
Ratings
Rezolute: Buy Rating Reiterated as FDA Engagement and Strong HI Data Support Unchanged $6 Price Target
11d ago
Rezolute: Buy Rating Reaffirmed as FDA Catalysts Support CGM‑Driven Upside, Price Target Maintained at $6
PremiumRatingsRezolute: Buy Rating Reaffirmed as FDA Catalysts Support CGM‑Driven Upside, Price Target Maintained at $6
1M ago
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
Premium
TipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
3M ago
Rezolute price target raised to $11, named a Best Idea at Guggenheim
Premium
The Fly
Rezolute price target raised to $11, named a Best Idea at Guggenheim
4M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―